neurocare group AG announces the recent initiation of a phase III trial examining the cost-effectiveness of TMS for patients with OCD resistant to exposure therapy
MUNICH, June 08, 2022 (GLOBE NEWSWIRE) — neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance enabling clinicians to deliver the best practices, is pleased to announce that enrolling patients has recently begun a Phase III clinical trial evaluating the cost-effectiveness of repetitive low-frequency transcranial magnetic stimulation (rTMS) for patients with obsessive-compulsive disorder (OCD ) resistant to exposure therapy. The study is being conducted in collaboration with the University Medical Centers Amsterdam (UMC).
“Despite proven efficacy, rTMS for OCD is not yet covered by the Dutch health insurance system while rTMS for treatment-resistant depression is. This trial aims to establish the added value of rTMS when combined with exposure and response prevention therapy in patients with OCD.” explains Tom Mechtersheimer, founder and CEO of neurocare group AG. “Once the cost-effectiveness of the combination therapy has been proven, the results of the study could lead to the addition of rTMS to health insurance coverage in the Netherlands and therefore the treatment would be available. for more people with OCD.We are confident that the study will confirm that the integrated treatment approach leads to long-lasting clinical results as well as a significant decrease in healthcare costs due to chronicity and low participation in social and educational/professional aspects of patients with OCD.”
The study is a randomized, double-blind, multicenter, placebo-controlled trial with an intervention phase of 5-7 weeks and a follow-up phase of 12 months. The study includes 250 adult patients with OCD (18 years and older) who show no or insufficient response to exposure and response prevention (ERP) and evaluates the cost-effectiveness of repetitive TMS at low frequency (1 Hz) versus pre-supplementary motor area therapy (pre-SMA) versus sham rTMS at pre-SMA as adjuvant exposure therapy with response prevention (ERP). Treatment consists of 4 times/week rTMS combined with ERP for at least 5 weeks (20 sessions), with an optional extension phase of 1 or 2 weeks and a maximum of 28 sessions in total.
About neurocare group AG:
neurocare innovates in mental health and performance. We offer the first digital therapy platform (DTP) that enables clinicians to deliver best practices. Our integrated and personalized therapeutic approach is based on a solid experience in clinical sciences with more than 20 years of research and technological development. Our business is driven by two strong growth channels: building our own clinics and supplying our unique DTP to third parties. We currently treat more than 2,000 patients a year in our own clinics and serve many third-party clients with our know-how in technology, training and therapy. www.neurocaregroup.com
neurocare group SA
This content was posted through the press release distribution service on Newswire.com.